聚腺苷二磷酸核糖聚合酶抑制剂rucaparib
发布时间：2019-08-14 21:01
【摘要】：近年来乳腺癌、卵巢癌、胰腺癌等实体瘤的发病率逐年增加,临床上还缺乏有效的治疗药物。作为第1个用于人类癌症疗法的聚腺苷二磷酸核糖聚合酶(PARP)抑制剂,临床前研究表明rucaparib可明显抑制乳腺癌、卵巢癌等实体瘤。临床研究显示rucaparib具有良好的安全性和有效性。主要从rucaparib的药物概况、相关背景、合成路线、临床前研究和临床研究方面进行介绍。
[Abstract]:In recent years, the incidence of breast cancer, ovarian cancer, pancreatic cancer and other solid tumors has increased year by year, and there is still a lack of effective drugs in clinic. As the first polyadenosine diphosphate ribose polymerase (PARP) inhibitor for human cancer therapy, preclinical studies have shown that rucaparib can significantly inhibit breast cancer, ovarian cancer and other solid tumors. Clinical studies have shown that rucaparib has good safety and effectiveness. This paper mainly introduces the drug situation, related background, synthetic route, preclinical research and clinical research of rucaparib.
【作者单位】： 天津药物研究院;
【分类号】：R979.1
本文编号：2526800
[Abstract]:In recent years, the incidence of breast cancer, ovarian cancer, pancreatic cancer and other solid tumors has increased year by year, and there is still a lack of effective drugs in clinic. As the first polyadenosine diphosphate ribose polymerase (PARP) inhibitor for human cancer therapy, preclinical studies have shown that rucaparib can significantly inhibit breast cancer, ovarian cancer and other solid tumors. Clinical studies have shown that rucaparib has good safety and effectiveness. This paper mainly introduces the drug situation, related background, synthetic route, preclinical research and clinical research of rucaparib.
【作者单位】： 天津药物研究院;
【分类号】：R979.1
【相似文献】
相关期刊论文 前1条
1 耿元硕;胡珀;王欣;刘超;李志裕;;聚腺苷二磷酸核糖聚合酶抑制剂Rucaparib的合成研究[J];精细化工中间体;2012年05期
，本文编号：2526800
本文链接：https://www.wllwen.com/yixuelunwen/yiyaoxuelunwen/2526800.html
最近更新
教材专著
